The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane. M. Harper, et al.
Gynecologic Oncology, April 2019 – Download the article
The publication has been featured in The Lancet Oncology and Medpage Today